Table 2.
Clinical activity endpoints in the full analysis population.
| All patients (n = 30) | 200 mg cohort (n = 15) | 300 mg cohort (n = 15) | |
|---|---|---|---|
| Confirmed overall response rate | 21 (70%; 51–85) | 12 (80%; 52–96) | 9 (60%; 32–84) |
| Disease control rate | 25 (83%; 65–94) | 13 (87%; 60–98) | 12 (80%; 52–96) |
| Best overall response | |||
| Confirmed partial response | 21 (70%) | 12 (80%) | 9 (60%) |
| Stable disease | 4 (13%) | 1 (7%) | 3 (20%) |
| Progressive disease | 3 (10%) | 1 (7%)a | 2 (13%) |
| Not evaluable | 2 (7%) | 1 (7%) | 1 (7%) |
| Median duration of response, months | 12.0 (8.3–14.9) | 12.2 (8.3–16.9) | 10.2 (1.6–15.7) |
| Median progression free survival, months | 12.9 (9.2–16.6) | 15.8 (9.2–17.0) | 10.7 (2.5–16.6) |
| Median overall survival, months | 33.7 (18.4–46.4) | 28.6 (17.8-NA) | 33.7 (5.2–46.4) |
Data are n (%) or median (95% CI). All assessments were based on investigators’ evaluation.
a
This patient experienced PR and PD response at 4 and 8 weeks, and continued AZD3759 treatment for 21.5 months because of potential benefit assessed by investigator after first disease progression.